Skip to main content
Clinical Trials/NCT04308525
NCT04308525
Unknown
Not Applicable

Optimising Microsurgical Reconstruction After Advanced Head and Neck Cancers - Enhanced Recovery and Improved Clinical Pathway

Rigshospitalet, Denmark1 site in 1 country25 target enrollmentJune 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Head and Neck Cancer
Sponsor
Rigshospitalet, Denmark
Enrollment
25
Locations
1
Primary Endpoint
Length of stay (LOS)
Last Updated
6 years ago

Overview

Brief Summary

This study aims to improve the peri- and postoperative care regimen for patients undergoing microvascular reconstruction after head and neck cancer by introducing an enhanced recovery after surgery (ERAS) programme.

Detailed Description

Advanced stage head and neck cancers have a poor prognosis and a 5-year survival rate of as low as 35-37%. The treatment is complex and often requires a multidisciplinary approach including surgery. The goal besides removal of the cancer is to restore function and appearance. If possible, both resection as well as immediate reconstruction will be performed during the same surgical procedure. Due to the large bone- and soft tissue loss following the ablative procedure, local solutions are often inadequate for reconstruction. In addition, many patients require post-operative radiotherapy, which may result in tightness of scar tissue and impaired function. In these cases it is necessary to perform the reconstruction using a free flap. Free flap reconstruction involves tissue taken from other parts of the body, that is transplanted along with the associated blood vessels to the reconstruction site. The vessels of the flap are usually anastomosed to the vessels of the neck (microvascular reconstruction) and the transplanted tissue thereby obtains a blood supply at its new location. Head and neck cancer patients are usually reconstructed using the free fibular flap, the latissimus dorsi flap, the radial forearm flap or the anterolateral thigh flap. The combination of complicated surgery and often malnourished patients with a low body mass index (BMI), that typically suffer from tobacco and alcohol abuse, commonly lead to postoperative ICU treatment and complications. The most common are infections, re-operations, delayed wound healing and refeeding syndrome, which is reported in up to 35% of patients undergoing major surgery for head and neck cancer. Even with successful reconstruction, many patients suffer from drooling, lack of adequate clenching, permanent gastric tube feeding, insufficient wound healing and a high recurrence rate. Enhanced recovery after surgery (ERAS) is a peri- and postoperative care concept designed to accelerate recovery and improve convalescence. It has previously been established as superior to conventional care for a wide variety of procedures. As one of the first departments in the world our department has successfully implemented an ERAS program for microsurgical patients that undergo breast reconstruction using autologous tissue. By utilizing our experience with ERAS and combining it with a review of our own patient data we have developed an ERAS protocol for microvascular reconstruction after ablative surgery for head and neck cancer.

Registry
clinicaltrials.gov
Start Date
June 1, 2019
End Date
March 31, 2021
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jens Hjermind Højvig

M.D., Ph.D.-student

Rigshospitalet, Denmark

Eligibility Criteria

Inclusion Criteria

  • Patients eligible for ablative surgery for head and neck cancer with primary microvascular reconstruction.

Exclusion Criteria

  • Patients with conditions leading to increased risk of thromboembolic events
  • Patients pre-operatively admitted to the ICU

Outcomes

Primary Outcomes

Length of stay (LOS)

Time Frame: 1 to 4 weeks

Time from surgery to discharge

Secondary Outcomes

  • Time to ambulation(1-7 days)
  • Complication-rate(30 days)
  • ICU LOS(1-2 days)
  • Incidence of re-operations(30 days)
  • Incidence of infections(30 days)

Study Sites (1)

Loading locations...

Similar Trials